

	<b>LEN + PEMBRO (N=355)</b>	<b>SUN (N=357)</b>
Median PFS <sup>a</sup> , mos (95% CI)	23.3 (20.8, 27.7)	9.2 (6.0, 11.0)
PFS HR (95% CI)	0.42 (0.34, 0.52)	
Median OS, mos (95% CI) <sup>b</sup>	NE (41.5-NE)	NE (38.4-NE)
OS HR (95% CI) <sup>b</sup>	0.72 (0.55-0.93)	
ORR, % (95% CI)	71.0 (66.3, 75.7)	36.1 (31.2, 41.1)
Relative risk, % (95% CI)	1.97 (1.69, 2.29)	
CR, %	17.2	4.2
Median DOR, mos (95% CI)	26.0 (22.2, 41.4)	14.7 (9.4, 16.8)
Data cutoff: March 31, 2021 (7 months of additional follow-up from the primary analysis). <sup>a</sup> PFS was the primary endpoint in the primary analysis; <sup>b</sup> OS was previously reported at Kidney Cancer Research Summit, 2021. CI, confidence interval; CR, complete response; DOR, duration of response; HR, hazard ratio; LEN, lenvatinib; mos, months; NE, not estimable; OS, overall survival; ORR, overall response rate; PEMBRO, pembrolizumab; PFS, progression-free survival; SUN, sunitinib.		